Vinflunine Tartrate |
| Catalog No.GC13815 |
Etanercept is an inhibitor of the inflammatory factor TNF-α and is mainly used for the clinical treatment of rheumatoid arthritis .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1201898-17-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Etanercept is an inhibitor of the inflammatory factor TNF-α and is mainly used for the clinical treatment of rheumatoid arthritis (RA), ankylosing spondylitis, and uveitis [1-3]. Etanercept can competitively inhibit the binding of two subtypes of TNF (TNF-α and TNF-β) to their cell surface receptor (TNFR) and further prevent TNF-α and TNF-β from exerting their biological effects [4].
In vitro, etanercept(20 or 50 µg/mL;7 h) reduced endothelial cell tube formation by inhibiting activation of the NF-κB signaling pathway[7]. The protective effect of etanercept(24h)lies in the restoration of autophagy against TNF-induced endothelial damage in EA.hy926 endothelial cells [5].
Etanercept treatment(0.8 mg/kg/week; 12 weeks;i.p.) significantly restored endothelium-dependent vasorelaxation and resulted in decreased serum levels of TNF-α and increased eNOS expression in rats exposed to CD[6].
References:
[1]. Padilla-Mart EM, Romero SC, et,al. (2019) Drug levels and antibodies against TNF-blockers in spondyloarthritis and rheumatoid arthritis are associated with the activity but they do not predict it. Curr Rheumatol Rev 15:329-335
[2]. D'Adamio S, Silvaggio D, et,al. Pharmacotherapeutic management of psoriasis in adolescents and children. Expert Opin Pharmacother. 2019 Oct;20(14):1777-1785. doi: 10.1080/14656566.2019.1636032. Epub 2019 Jul 4. PMID: 31271541.
[3]. Bartalena L. Commentary: rituximab, adalimumab, etanercept, tocilizumab--are biologics the future for Graves' orbitopathy? Ophthalmic Plast Reconstr Surg. 2014 Sep-Oct;30(5):420-3. doi: 10.1097/IOP.0000000000000221. PMID: 25025391.
[4]. Lim H, Lee SH, et,al. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Int J Mol Sci. 2018 Mar 7;19(3):768. doi: 10.3390/ijms19030768. PMID: 29518978; PMCID: PMC5877629.
[5]. Barbati C, Colasanti T, et,al. Up-regulation of autophagy by etanercept treatment results in TNF-induced apoptosis reduction in EA.hy926 endothelial cell line. Clin Exp Rheumatol. 2021 May-Jun;39(3):606-611. doi: 10.55563/clinexprheumatol/uiqdtq. Epub 2020 Sep 3. PMID: 32896251.
[6]. Răzvan-Valentin S, GÜler SA, et,al. Etanercept Prevents Endothelial Dysfunction in Cafeteria Diet-Fed Rats. Int J Environ Res Public Health. 2022 Feb 14;19(4):2138. doi: 10.3390/ijerph19042138. PMID: 35206342; PMCID: PMC8872388.
[7]. Yao Y, Cai Y, et,al. Etanercept as a TNF-alpha inhibitor depresses experimental retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2021 Mar;259(3):661-671. doi: 10.1007/s00417-020-04956-6. Epub 2020 Oct 12. PMID: 33043386.
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *